Abstract:

Most patients with end-stage renal disease (ESRD) suffer  from cardiovascular disease. Treatment with mineralocorticoid receptor antagonists (MRAs) reduce cardiac risk effectively. MRAs not only have the potential to reduce blood pressure but also to promote favorable remodeling of cardiac ventricle. Recent researches have suggested that MRAs can improve survival in ESRD patients, though few parts of patients have the risks of hyperkalemia and reduced renal function. In this review, we highlight the potential cardiovascular benefits and review the evident risks of MRAs in ESRD patients.